RedHill Biopharma (RDHL) Study Shows opaganib's Strong Inhibition of COVID-19 Delta Variant

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/28/2026

1. SYNA
2. ON
3. SPY
4. MU
5. AAPL
6. VEON
7. DRI
8. NKE
9. USO
10. NVDA

Go back to RedHill Biopharma (RDHL) Study Shows opaganib's Strong Inhibition of COVID-19 Delta Variant

RedHill Biopharma (RDHL) Tops Q2 EPS by 6c, Revenue Misses Consensus

August 26, 2021 7:10 AM EDT

RedHill Biopharma (NASDAQ: RDHL) reported Q2 EPS of ($0.06), $0.06 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $21.5 million versus the consensus estimate of $25.02 million.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

... More